Global Accreditation Failures: Links Between China, India, and U.S. Corporations Jeopardize Public Health and Safety

NEW YORK - Jan. 17, 2025 - PRLog -- An alarming pattern of contamination in medications originating from CHINA https://www.pharmacytimes.com/view/contaminated-compounding-drug-shipments-coming-from-china-fda-warns and INDIA https://www.cidrap.umn.edu/resilient-drug-supply/tainted-drug-deaths-weak-regulation-corrode-confidence-indian-drugs echoes the same systemic issues faced by major U.S. pharmaceutical giants Pfizer  and Johnson & Johnson Daryl Guberman, CEO of Guberman-PMC, LLC, highlights how global accreditation failures and conflicts of interest, particularly involving ANSI-ANAB, IAF, and ILAC (International Laboratory Accreditation Cooperation-Australia) , are enabling unqualified laboratories and manufacturing facilities to operate unchecked.

The International Accreditation Forum (IAF Incorporated in Delaware), founded by ANSI-ANAB, has a troubling history of compromised oversight. Between 2015 and 2021, the leadership of IAF was handed over to a Chinese national, Xiao Jianhua (involved in US and international quality since 1994 and is mandated by Communist China to take information via the China National Intelligence Law Article #7). He also served as the chief executive of the China National Accreditation Service (CNAS) in Beijing, China. This dual role created significant conflicts of interest, as CNAS, under Xiao's leadership, issued certificates to facilities such as the Wuhan Institute of Virology (WIV), despite documented deficiencies in safety and staff training.

The Wuhan Connection

In 2017, Xiao Jianhua was photographed at the Wuhan Institute of Virology's Biosafety Level 4 (BSL-4) laboratory issuing a certification to a lab that U.S. experts later determined was unqualified to handle high-level contagions. A 2018 report from American contingents visiting the lab revealed critical concerns, including a lack of adequately trained technicians . By 2019, the CDC published a training document (Vol. 25) emphasizing the importance of skilled personnel as the first line of defense in maintaining containment in biosafety labs—a standard the Wuhan lab was clearly unprepared to meet.

Adding to these concerns, 2017 Pamela Sale, Vice President of Laboratory Accreditation for ANSI-ANAB, was giving a deposition in Texas, where she confessed "one of the issues is that there is no commonly agreed-upon set of standards that forensics labs around the country have to follow. Instead, there are informal guidelines that labs can choose to follow or not". This confession underscores systemic failures in the global accreditation system and raises serious questions about the release of the contagion from the Wuhan laboratory.

Moreover, ANSI and ANAB act as the underwriters for the International Accreditation Forum (IAF) and the International Laboratory Accreditation Cooperation (ILAC). This means they bear full legal responsibility for any systematic or product failures arising under their accreditation schemes. This critical detail highlights the accountability of these organizations in global quality assurance failures.

Guberman also highlights a recent effort by ANSI and ANAB to establish a unified global accreditation entity named Global Accreditation Cooperation (GLOBAC) a unification of IAF-ILAC. He argues that this move is intended to dissolve ANSI and ANAB's liability while preserving their control over global accreditation processes.

Global Implications of Compromised Accreditation

The IAF's ties to China especially the years 2015-2021, where federal agencies and corporations sit on ANSI-ANAB's boards, highlight a systemic failure to uphold impartial oversight. This conflict of interest extends to the international pharmaceutical supply chain, where:

1.          China and India's Substandard Manufacturing Practices: Repeated contamination scandals in medications exported globally mirror quality issues seen in U.S.-based corporations like Pfizer and Johnson & Johnson.

2.          Accreditation Conflicts: The same entities responsible for oversight—ANSI-ANAB, IAF, and ILAC—also certify these facilities, leading to compromised accountability.

3.     Regulatory Capture: Federal agencies such as the FDA, CDC, NIH, USDA sit on ANSI-ANAB boards alongside corporate giants, blurring the line between regulator and regulated. Also the FDA is not just a member on ANSI-ANAB board they are also a customer. The also approved ANSI-ANAB for  3^rd party food safety accreditation https://www.naccho.org/blog/articles/ansi-recognized-by-fda-under-the-accredited-third-party-certification-program

ALL INFORMATION:
1, Pfizer, J&J,
2, 2018 US scientists report about lack of trained technicians in Wuhan China.
3. Volume 25 May 2019 CDC training document
4. Pamela Sale VP Laboratory accreditation for ANSI-ANAB Texas deposition
All contained in this link:  https://www.prlog.org/13052548-covid-vaccine-makers-shielded-until-2029-qa-expert-daryl-guberman-reveals-path-to-justice.html

A Call for Reform

Guberman warns that unless global accreditation systems are reformed, public health and safety will remain at risk. He emphasizes that ensuring transparency, accountability, and separation between regulatory bodies and corporate entities is essential to restoring trust in global supply chains and accreditation processes. The same issues are similar in the aerospace, automotive, electronics industries.